Clinical trials: Cancer, Carcinoma
Stage III Non-small Cell Lung Cancer, Unresectable Stage III NSCLC
In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy
PulmoPrint is a clinical study at the University Medical Center Groningen (UMCG) that investigates why some patients with unresectable stage III lung cancer don't respond to immunotherapy after chemoradiotherapy.
- Trial name
- PulmoPrint (NCT07653438)
- Testing
- Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study
This multicentre, randomized controlled trial evaluates the effect and safety of integrating acupuncture with immunotherapeutic sensitization in treating NSCLC.
- Trial name
- NCT06461338
- Testing
- acupuncture
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IA Endometrial Carcinoma
- Trial name
- NCT01943058
- Testing
- megestrol acetate, levonorgestrel-releasing intrauterine system, laboratory biomarker analysis
- Sponsor
- University of Southern California
Advanced Lung Cancer
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants…
- Trial name
- NCT06892548
- Testing
- BNT324, BNT327
- Where
- 91 sites in United States, Australia and 8 more
- Volunteers
- 594 people
- Sponsor
- BioNTech SE
Esophageal Squamous Cell Carcinoma
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of carrelizumab plus concurrent chemoradiotherapy compared with placebo plus concurrent…
- Trial name
- NCT06048926
- Testing
- Carrelizumab, Paclitaxel injection, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer, Pulmonary Stereotactic Radiotherapy
Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions
Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites.
- Trial name
- NCT07401615
- Where
- 11 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Clinico Humanitas
Hepatocellular Carcinoma (HCC), Second Line Treatment
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or…
- Trial name
- NCT04522908
- Testing
- Cabozantinib Oral Tablet
- Where
- 10 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non Small Cell Lung Cancer
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small…
- Trial name
- NCT03425006
- Testing
- Itacitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pennsylvania
Non-Small Cell Lung Cancer
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
- Trial name
- ENSPIRIT (NCT01630733)
- Testing
- Custirsen, Docetaxel
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 664 people
- Sponsor
- Achieve Life Sciences
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Locally Advanced Head and Neck Carcinoma
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
- Trial name
- NeckTAR-IN (NCT07178847)
- Testing
- blood sampling
- Where
- 4 sites in France
- Volunteers
- 59 people
- Sponsor
- Centre Jean Perrin
Hepatocellular Carcinoma, Metastasis
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.
- Conditions
- Hepatocellular Carcinoma, Metastasis, Cholangiocarcinoma
- Trial name
- NCT02683538
- Testing
- Separable cluster electrode (Octopus®)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Hospital
Rupture, Spontaneous, Rupture Liver
A Comparison Between Child-Pugh and Albumin-Bilirubin Scores
To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma
- Conditions
- Rupture, Spontaneous, Rupture Liver, Hepatocellular Carcinoma, Hepatic Impairment
- Trial name
- NCT03534843
- Testing
- Liver resection, Transcatheter arterial embolization
- Volunteers
- 230 people
- Sponsor
- Huazhong University of Science and Technology
Squamous Cell Head and Neck Carcinoma
Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.
The purpose of this study is to demonstrate that induction chemotherapy followed by radiation therapy plus Cetuximab will give better results than the validated treatment (chemoradiotherapy), for treatment of locoregional…
- Trial name
- 2007/02 (NCT01233843)
- Testing
- carboplatin, 5 fluorouracil, radiation therapy
- Where
- France
- Volunteers
- 370 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Esophageal Squamous Cell Carcinoma, Tislelizumab
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation
- Trial name
- LATE (NCT05394415)
- Testing
- Tislelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Lung Cancer, Non Small Cell Lung Cancer
Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy
The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung cancer patients and individuals without lung cancer ("healthy" controls).
- Trial name
- NCT04556435
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Breathe BioMedical Inc
Hepatocellular Carcinoma
Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence in HCC…
- Trial name
- NCT03273608
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Nonsmall Cell Lung Cancer
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following…
- Trial name
- NCT02981108
- Testing
- HS-10296
- Where
- 10 sites in United States
- Volunteers
- 364 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
HPV-Related Oropharynx Squamous Cell Carcinoma
The Minimalist Trial-2
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA.
- Trial name
- MINT-2 (NCT06702033)
- Testing
- Radiation therapy, Cisplatin, Surgery
- Where
- 3 sites in United States
- Volunteers
- 142 people
- Sponsor
- Washington University School of Medicine
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.